Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a sell rating to a hold rating in a research report report published on Friday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

Several other brokerages have also recently weighed in on TTPH. BMO Capital Markets increased their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an outperform rating in a report on Wednesday, October 4th. Needham & Company LLC restated a hold rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. HC Wainwright increased their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a buy rating in a report on Monday, November 6th. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $0.01 during mid-day trading on Friday, reaching $6.51. The company had a trading volume of 286,700 shares, compared to its average volume of 458,989. The stock has a market cap of $334.71, a PE ratio of -2.28 and a beta of 2.51. Tetraphase Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) EPS. equities analysts expect that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage purchased 3,880 shares of the stock in a transaction on Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $107,000. Brighton Jones LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $108,000. AXA bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $132,000. Voya Investment Management LLC raised its position in shares of Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 3,104 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $147,000. 58.15% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals (TTPH) Rating Increased to Hold at Zacks Investment Research” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/01/15/tetraphase-pharmaceuticals-ttph-rating-increased-to-hold-at-zacks-investment-research.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related stocks with our FREE daily email newsletter.